PDS Biotechnology Corp
For the period ended Aug 11, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 11, 2026 · Filed Aug 11, 2026
Use the contents to explore the available documents and sections.
PDSB$1.23+5.1%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · References
References
| 1. | Aruquipa MPS et al, Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. A literature review; ecancer 2024, 18:1771. |
| 2. | Eade AV et al; Tumor-Targeted IL-12 (NHS-IL12) with Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Non-randomized Phase II Tria; JCO Oncol Adv 3, e2500173 (2026) Vol. 3 #1. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.